A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor

The P2X7 receptor is an ATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Understanding species-specific pharmacological effects of existing antagonists has been challenging, in part due to the dearth of molecular information on receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the full-length wild-type human P2X7 receptor in apo closed and ATP-bound open state conformations and draw comparisons with structures of other orthologs. We also report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a unique polycyclic scaffold. Functional and structural analysis reveal how this optimized ligand, termed UB-MBX-46, interacts with the classical allosteric pocket of the human P2X7 receptor with subnanomolar potency and high selectivity, revealing its significant therapeutic potential.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-09-15
DOI
https://doi.org/10.1038/s41467-025-62643-8
Citations
4
Primary Topic
Adenosine and Purinergic Signaling
Type
article
Field-Weighted Citation Impact
4.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor

Steven Mansoor, Santiago Vázquez, Eva Tzortzini, Andreea L. Turcu et al.
4 citations
Nature Communications
Adenosine and Purinergic Signaling
4.47
article

A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor

Steven Mansoor, Santiago Vázquez, Eva Tzortzini, Andreea L. Turcu, Annette Nicke, Adam Oken, Marta Barniol‐Xicota, Jessica Nagel, Antonios Kolocouris, Yong‐Chul Kim, Christa Elisabeth Müller, Garam Kim, J Seidler, So-Deok Lee, Kyriakos Georgiou, Franka G. Westermann
article en
4 citations

Abstract

The P2X7 receptor is an ATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Understanding species-specific pharmacological effects of existing antagonists has been challenging, in part due to the dearth of molecular information on receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the full-length wild-type human P2X7 receptor in apo closed and ATP-bound open state conformations and draw comparisons with structures of other orthologs. We also report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a unique polycyclic scaffold. Functional and structural analysis reveal how this optimized ligand, termed UB-MBX-46, interacts with the classical allosteric pocket of the human P2X7 receptor with subnanomolar potency and high selectivity, revealing its significant therapeutic potential.

Nature CommunicationsVol. 16(1)
University of Bonn (DE), Oregon Health & Science University (US), Institut Barcelona d'Estudis Internacionals (ES), National and Kapodistrian University of Athens (GR), Barcelona Biomedical Research Park (ES), Gwangju Institute of Science and Technology (KR), Institut Botànic de Barcelona (ES), Institute for Research in Biomedicine (ES), Universitat de Barcelona (ES), Ludwig-Maximilians-Universität München (DE)
U.S. Department of Energy, American Heart Association, Oregon Health and Science University, Ministerio de Ciencia, Innovación y Universidades, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, National Institutes of Health, Office of Science, European Regional Development Fund, Agencia Estatal de Investigación, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, Biological and Environmental Research, Precursory Research for Embryonic Science and Technology
Openalex Percentile: Top 5%
Adenosine and Purinergic Signaling
4.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.